Olaparib has changed how certain cancers linked to BRCA1 and BRCA2 mutations are treated. Rather than attacking all rapidly dividing cells, it targets a weakness in the way some cancer cells repair damaged DNA.
This targeted approach may help delay cancer progression, reduce the risk of recurrence in selected patients and extend survival in certain treatment settings. However, olaparib is not suitable for every person with cancer or every BRCA mutation. Genetic test results, cancer type, stage, previous treatment and overall health must all be considered.
| Treatment Detail | Information | Why It Matters |
|---|---|---|
| Generic name | Olaparib | Identifies the active ingredient in the medicine |
| Common brand name | Lynparza | The brand under which olaparib is commonly available |
| Medicine type | PARP inhibitor | Blocks proteins involved in repairing damaged DNA |
| Treatment approach | Targeted cancer therapy | Targets specific weaknesses within certain cancer cells |
| Main biological target | PARP enzymes involved in DNA repair | Prevents cancer cells from repairing some forms of DNA damage |
| Relevant biomarkers | BRCA1, BRCA2 and, in some settings, other homologous recombination repair changes | Helps doctors determine whether treatment may be suitable |
| Cancer types commonly associated with its use | Ovarian, breast, pancreatic and prostate cancer | Approved treatment settings differ by cancer type and patient profile |
| Form | Oral tablets | Allows the medicine to be taken by mouth |
| Treatment role | Active treatment, adjuvant treatment or maintenance therapy, depending on the cancer | The treatment goal varies according to the cancer and its stage |
| Prescription status | Prescription-only medicine supervised by an oncology specialist | Requires specialist assessment, prescribing and ongoing monitoring |
DNA damage occurs naturally as cells grow and divide. Healthy cells use several repair systems to correct this damage.
Two of these systems are especially relevant to olaparib:
A BRCA-mutated cancer cell may already struggle with homologous recombination repair. Olaparib blocks the PARP pathway as well, leaving the cell with fewer ways to correct DNA damage.
As the damage accumulates, the cancer cell may become unable to continue dividing. Healthy cells with functioning BRCA pathways may be better able to survive this pressure, although they can still be affected. This is why olaparib can cause significant side effects despite being a targeted treatment.
Olaparib has established roles in selected ovarian, breast, pancreatic and prostate cancers. The exact eligibility requirements differ considerably.
| Cancer Type | Potential Role of Olaparib | Important Selection Factors |
|---|---|---|
| Advanced ovarian, fallopian tube or primary peritoneal cancer | First-line maintenance after a complete or partial response to platinum-based chemotherapy | Harmful or suspected harmful germline or somatic BRCA mutation |
| Recurrent ovarian, fallopian tube or primary peritoneal cancer | Maintenance after response to platinum-based chemotherapy | BRCA status, previous treatment and local approval requirements |
| HRD-positive advanced ovarian cancer | Maintenance with bevacizumab after first-line platinum-based chemotherapy and bevacizumab | BRCA mutation and/or genomic instability confirming HRD-positive status |
| High-risk early breast cancer | Adjuvant treatment after neoadjuvant or adjuvant chemotherapy | Germline BRCA mutation, HER2-negative disease and defined high-risk features |
| Metastatic breast cancer | Targeted treatment for selected previously treated patients | Germline BRCA mutation, HER2-negative disease and previous chemotherapy |
| Metastatic pancreatic adenocarcinoma | Maintenance after initial platinum-based chemotherapy | Germline BRCA mutation and no progression after at least 16 weeks of first-line platinum treatment |
| Metastatic castration-resistant prostate cancer | Treatment alone or, in selected cases, with abiraterone and prednisone or prednisolone | Relevant germline or somatic mutation, previous treatment and disease setting |
The goal of olaparib depends on when and why it is prescribed.
When olaparib is used as maintenance therapy, the intention is often to preserve the benefit achieved with chemotherapy and delay the return or progression of cancer.
Maintenance treatment does not necessarily mean that all cancer has disappeared. It means that treatment is being continued to help control the disease after it has responded or remained stable.
For selected patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer, adjuvant olaparib may be used after chemotherapy and local treatment.
In the OlympiA trial, olaparib improved invasive disease-free survival and overall survival compared with placebo. This does not mean that recurrence can be prevented in every patient, but it supports olaparib as an important additional treatment for appropriately selected high-risk disease.
BRCA and related HRR testing can identify a biological weakness that may be targeted with a PARP inhibitor.
This allows treatment to be selected using the molecular features of the cancer rather than relying only on where the tumour began.
Olaparib is taken by mouth, which may reduce the number of hospital visits needed for drug administration. However, regular appointments, laboratory tests and scans are still required.
Oral treatment should not be considered automatically easier or safer than intravenous therapy. Consistent dosing and close monitoring remain essential.
The following trials examined olaparib in different cancers and treatment settings. Results should not be compared directly because the patient groups, treatment stages and study endpoints were different.
| Clinical Trial | Cancer Setting | Key Finding |
|---|---|---|
| SOLO-1 | Newly diagnosed advanced BRCA-mutated ovarian cancer after response to platinum chemotherapy | Olaparib significantly extended progression-free survival compared with placebo |
| OlympiA | Germline BRCA-mutated, HER2-negative, high-risk early breast cancer | Olaparib improved invasive disease-free survival and overall survival |
| OlympiAD | Germline BRCA-mutated, HER2-negative metastatic breast cancer | Median progression-free survival was 7.0 months with olaparib and 4.2 months with physician-selected chemotherapy |
| POLO | Germline BRCA-mutated metastatic pancreatic cancer without progression after platinum chemotherapy | Median progression-free survival was 7.4 months with olaparib and 3.8 months with placebo; the overall-survival difference was not statistically significant |
| PROfound | HRR-mutated metastatic castration-resistant prostate cancer after previous hormonal therapy | Olaparib improved radiological progression-free survival; benefit varied according to the specific HRR gene alteration |
An oncologist may consider olaparib when several clinical and molecular conditions are met.
Testing may use a blood, saliva or tumour-tissue sample. In some prostate cancer settings, circulating tumour DNA from a blood sample may also be considered.
| Type of Test | What It Looks For | Why It Matters |
|---|---|---|
| Germline BRCA testing | Inherited BRCA1 or BRCA2 mutations | May determine treatment eligibility and reveal possible implications for relatives |
| Somatic tumour testing | Mutations found within cancer tissue | May identify an acquired BRCA or other HRR alteration |
| HRD testing | BRCA mutations and/or genomic instability | May help guide selected ovarian cancer maintenance strategies |
| HRR gene panel | Changes in genes involved in homologous recombination repair | Used in certain prostate cancer treatment decisions |
| Confirmatory testing | Verification of a result using an appropriate validated test | Helps ensure that treatment is based on a clinically meaningful alteration |
Before treatment begins, the healthcare team may review:
The standard reference dose for adults is commonly 300 mg twice daily, but the prescribed dose can differ according to kidney function, side effects and medicine interactions.
Treatment duration depends on the cancer and treatment goal.
For first-line maintenance of advanced BRCA-mutated ovarian cancer, treatment may continue for up to two years when there is no radiological evidence of disease. Selected patients with evidence of disease who may continue to benefit can sometimes remain on treatment longer.
For high-risk early breast cancer, adjuvant olaparib is generally given for up to one year.
In recurrent ovarian, metastatic breast, pancreatic and prostate cancer settings, treatment may continue until:
Regular monitoring helps the oncology team evaluate both treatment response and safety.
| Monitoring Area | What May Be Checked | Why It Is Important |
|---|---|---|
| Blood-cell counts | Haemoglobin, white cells, neutrophils and platelets | Detects anaemia, infection risk, bleeding risk and prolonged bone marrow suppression |
| Liver function | Bilirubin and liver enzymes | Identifies possible liver injury |
| Kidney function | Creatinine and estimated filtration rate | Helps determine whether dose adjustment is needed |
| Treatment response | Scans, symptoms, examination and relevant tumour markers | Assesses whether the cancer remains controlled |
| Respiratory health | New cough, fever, wheezing or breathlessness | Helps identify possible pneumonitis or other lung problems |
| Clotting symptoms | Leg swelling, limb pain, chest pain and sudden breathlessness | Supports early detection of venous thromboembolism |
| Treatment tolerance | Fatigue, nausea, appetite, bowel symptoms and daily functioning | Guides supportive care and possible dose changes |
| Medicine review | New prescriptions, supplements and dietary products | Reduces the risk of clinically important interactions |
| Possible Problem | Warning Signs That Require Medical Advice | Recommended Action |
|---|---|---|
| Severe anaemia or bone marrow suppression | Extreme tiredness, weakness, dizziness, breathlessness, pale skin, frequent infections or unusual bleeding | Contact the oncology team promptly for assessment and blood tests |
| Myelodysplastic syndrome or acute myeloid leukaemia | Persistent low blood counts, fever, weight loss, repeated infections, bruising or bleeding | Seek urgent medical assessment and specialist investigation |
| Pneumonitis | New or worsening cough, fever, wheezing or difficulty breathing | Contact the oncology team immediately; urgent assessment may be required |
| Blood clot or pulmonary embolism | Pain or swelling in an arm or leg, sudden shortness of breath, rapid breathing or chest pain | Seek emergency medical care, particularly for chest pain or sudden breathing difficulty |
| Liver injury | Yellow skin or eyes, dark urine or pain on the right side of the abdomen | Contact the treating team immediately for liver-function assessment |
| Severe gastrointestinal problems | Inability to keep fluids down, persistent vomiting or signs of dehydration | Seek prompt medical advice to prevent or treat dehydration |
| Allergic reaction | Facial swelling, widespread rash or difficulty breathing | Stop taking further doses and seek emergency medical care immediately |
Olaparib is mainly processed through the CYP3A pathway. Medicines that strongly inhibit or induce this pathway can change the amount of olaparib in the body.
Patients should provide their healthcare team with a complete list of:
Olaparib can harm an unborn baby and may cause pregnancy loss.
According to the current US prescribing information:
Some cancers do not respond to olaparib, while others may initially respond and later begin to grow again.
Resistance can develop through several mechanisms. For example, cancer cells may partially restore BRCA-related DNA repair, change the way the medicine enters or leaves the cell, protect damaged DNA-replication structures or activate alternative survival pathways.
If the cancer progresses, the oncology team may consider:
Olaparib demonstrates how genetic information can guide cancer treatment. By targeting a DNA-repair weakness associated with BRCA and certain related mutations, it offers a more personalised option across several cancer types.
Its value depends on careful patient selection. The right biomarker, treatment stage, previous therapy and monitoring plan all contribute to whether olaparib can be used safely and effectively.
For eligible patients, olaparib may help preserve a response to chemotherapy, delay cancer progression, lower the risk of recurrence or improve survival in specific settings. These potential benefits must always be balanced against side effects, serious risks and the individual patient’s treatment priorities.
This information is intended for general education and does not replace medical advice. Olaparib should only be prescribed and monitored by a qualified oncology professional. Approved uses may vary by country.
